↑ 疾患リストへ ← 戻る

 162. 類天疱瘡(後天性表皮水疱症を含む。) [臨床試験数:49,薬物数:72(DrugBank:35),標的遺伝子数:23,標的パスウェイ数:118] 

Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04128176November 25, 201928 October 2019Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous PemphigoidAn Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous PemphigoidBullous PemphigoidDrug: Rituximab combined with OmalizumabUniversity of California, DavisNot recruiting18 Years90 YearsAll15Phase 3United States
2NCT04117932November 1, 201922 October 2019Efficacy and Safety of Ustekinumab in Bullous PemphigoidEfficacy and Safety of Ustekinumab in Bullous PemphigoidBullous PemphigoidDrug: UstekinumabCHU de ReimsNot recruiting18 Years90 YearsAll18Phase 2France
3NCT03295383July 11, 20194 November 2019Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidRandomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidSevere Forms of Mucous Membrane PemphigoidDrug: Rituximab 1g IV;Drug: Cyclophosphamide 50Mg Oral Tablet;Drug: Placebo of Rituximab;Drug: Placebo Oral TabletUniversity Hospital, RouenRecruiting18 Years80 YearsAll130Phase 3France
4NCT03926377April 20196 May 2019Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous PemphigoidInfluence of Dermocorticoids on Bone Mineral Density in Patients With Bullous PemphigoidOsteoporosis;Bullous PemphigoidProcedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionateCentre Hospitalier Universitaire, AmiensUniversity Hospital, RouenNot recruiting18 YearsN/AAll50Phase 4
5NCT04035733September 25, 20184 November 2019rVA576 in Adult Mild to Moderate Bullous Pemphigoid SubjectsA Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid SubjectsBullous Pemphigoid (BP)Biological: rVA576AKARI TherapeuticsRecruiting18 YearsN/AAll9Phase 2Germany;Netherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03636763September 201827 August 2018Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? : Multicenter Retrospective Study in France and SwitzerlandBullous PemphigoidDrug: data reportAssistance Publique Hopitaux De MarseilleRecruitingN/AN/AAll183Phase 1France
7EUCTR2017-002836-18-NL07/05/201828 February 2019A Clinical study to investigate if rVA576 is safe and has an effect on patients who have mild or moderate Bullous Pemphigoid (a blistering disorder where the skin forms tense blisters)A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjectsMild to Moderate Bullous Pemphigoid
MedDRA version: 20.0 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: rVA576
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: rVA576
Current Sponsor code: rVA576
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18-
Akari Therapeutics Plc.Authorised Female: yes
Male: yes
9Phase 2Germany;Netherlands
8JPRN-jRCTs05118006912/04/20182 April 2019Imatinib treatment of autoimmune bullous diseasesIntervention study on autoimmune bullous diseases with imatinib - IABDAutoimmune bullous disease including pemphigus group and pemphigoid group;D012872Imatinib 800 mg a day p.o. for seven days will be started within 14 days of starting steroid therapy (and when the bed is secured).Kenji KabashimaTakashi Nomura;Akihiko Kitoh;Tetsuya Honda;Gyohei Egawa;Yuichiro Endo;Yo Kaku;Atsushi OtsukaRecruiting20 years oldOne hundred years oldBoth10Phase 0none
9NCT03286582September 5, 201730 September 2019A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous PemphigoidA Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous PemphigoidBullous PemphigoidDrug: AC-203 1% Topical Ointment;Drug: Clobetasol 0.05% Topical OintmentTWi Biotechnology, Inc.Not recruiting20 Years90 YearsAll10Phase 2Taiwan
10NCT03099538August 15, 201726 August 2019Ixekizumab in the Treatment of Bullous PemphigoidIxekizumab in the Treatment of Bullous PemphigoidBullous Pemphigoid;PemphigoidDrug: IxekizumabMayo ClinicEli Lilly and CompanyNot recruiting18 YearsN/AAll6Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02993133December 20166 May 2019Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.Autoimmune Bullous DermatoseDrug: Cellcept® in autoimmune bullous dermatosesUniversity Hospital, LimogesNot recruiting18 YearsN/AAll53Phase 3France
12NCT02226146February 201611 June 2018Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous PemphigoidAn Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous PemphigoidPemphigoid, BullousBiological: BertilimumabImmune PharmaceuticalsNot recruiting60 YearsN/AAll11Phase 2United States;Israel
13NCT02874079December 201517 October 2016Genetic Susceptibility and Influence of the Microbiomae in Bullous PemphigoidGenetic Susceptibility and Influence of the Microbiomae in Bullous PemphigoidBullous PemphigoidOther: Blood sample and cotton skin swabsCHU de ReimsRecruiting18 YearsN/ABoth100N/AFrance
14NCT02502903June 20154 November 2019Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated DisordersSafety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.Bullous Pemphigoid (BP);Cold Agglutinin Disease (CAD);Warm Autoimmune Hemolytic Anemia (WAIHA);End-stage Renal Disease (ESRD)Drug: BIV009;Other: PlaceboBioverativ Therapeutics Inc.Celerion Clinical Research GmbH;Assign Data Management and Biostatistics GmbH;ABF Pharmaceutical Services GmbH;Quest Diagnostics;Covance Laboratories - ChantillyRecruiting18 YearsN/AAll122Phase 1Austria
15NCT02360202April 201516 December 2017Evaluation of Fluid Retention Due to Superpotent Topical CorticosteroidEvaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous PemphigoidBullous PemphigoidProcedure: Impedance analysis;Drug: Clobetasol Propionate cream treatmentUniversity Hospital, RouenSociété de Dermatologie FrançaiseRecruiting18 YearsN/AAll35Phase 4France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02365675January 20152 March 2015Wound Dressings for Pemphigus and PemphigoidAn Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and PemphigoidPemphigus;PemphigoidDevice: Cotton gauze with petrolatum;Device: Cellulose acetate with petrolatum;Device: Nanocrystalline silver (Acticoat);Device: Carboxymethylcellulose with ionic silver (Aquacel Ag)Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranRecruiting18 YearsN/ABoth12N/AMexico
17JPRN-UMIN0000154512014/11/132 April 2019Exploratory research on effectiveness and safety of Rituximab treatment including maintenance administration for steroid intractable autoimmune bullous diseases of the skin. Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) 2Pemphigus, PemphigoidRituximab 375mg/sqm, q1w, 4 doses.
Maintenance administration of rituximab is possible if PDA or BPDAI is between 1 and 10 on week 24 to 48
Department of Dermatology, Keio University School of MedicineHokkaido University, Kurume University, Okayama University, Kawasaki Medical SchoolNot Recruiting20years-old80years-oldMale and Female20Phase 1,2Japan
18NCT02126020November 201416 December 2017Topical Infliximab in Autoimmune Eyes With KeratoprosthesisTopical Infliximab in Autoimmune Eyes With KeratoprosthesisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane PemphigoidDrug: topical infliximabJames Chodosh, MD, MPHMassachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)Not recruiting18 Years80 YearsAll0Phase 1/Phase 2United States;Canada
19JPRN-jRCTs03118022001/05/201422 July 2019Rituximab treatment of blistering diseaseTreatment of refractory autoimmuno blistering disease with rituximabPemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoidInfusion of rituximab (1000mg) intravenously. Approximately two weeks after the first dose, a second dose of rituximab is administered in a similar manner.Miwa KanaokaAihara MichikoRecruiting20 age old80 age oldBoth10N/Anone
20NCT02149732May 20142 May 2016Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet TransplantationAn Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency PatientsLimbal Stem Cell Deficiency;Stevens-johnson Syndrome;Ocular Cicatricial Pemphigoid;Chemical BurnBiological: cultivated oral mucosal epithelial sheet transplantationSeoul National University HospitalMinistry of Health & Welfare, KoreaNot recruiting16 YearsN/ABothPhase 1/Phase 2Korea, Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21JPRN-UMIN0000029482013/04/012 April 2019Cultivated epithelial sheet transplantation for corneal epithelial stem cell deficiencya) Steven's Johnson Syndrome b) Ocular cicatricial pemphigoid c) Chemical/ Thermal Burns of the Cornea d) Gelatinous Drop Like Dystrophy e) Salzmann Corneal Degeneration f) Congenital AniridiaCorneal epithelial sheet transplantation
Cultivated eptihealial sheet transplantation will be perfored in the surgical department of Keio University Hospital. Simultaneous lamellar keratoplasty will be allowed.
Surgical procedure involves removal of all pannus and abnormal epithelial tissue, the use of 0.04% mitomycin C to prevent fibrosis, and transplantation of the cultivated sheet.
Department of Ophthalmology, Keio University School of MedicineNot Recruiting20years-oldNot applicableMale and Female5Not selectedJapan
22NCT02837965April 20138 August 2016Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous PemphigoidMulticenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous PemphigoidBullous PemphigoidDrug: treatment with topical superpotent corticosteroid therapy;Drug: treatment with systemic therapy (methotrexate);Drug: treatment systemic therapy (prednisone);Drug: treatment with systemic therapy (prednisone);Drug: treatment with systemic therapy (doxycycline)CHU de ReimsRecruiting18 YearsN/ABoth150N/AFrance
23EUCTR2011-004361-32-DE26/02/201311 April 2016Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoidEffect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid A prospective multi-centre randomised double-blind placebo-controlled pilot study - SICOPEMBullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal phase with severe itching. Between 10 to 30 percent of patients exhibit mucosal membrane involvement in addition to the skin lesions. ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Trade Name: Simvastatin-ratiopharm®
Product Name: Simvastatin-ratiopharm
Pharmaceutical Form: Capsule
CAS Number: 79902-63-9
Other descriptive name: SIMVASTATIN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Philipps-Universität MarburgNot RecruitingFemale: yes
Male: yes
Germany
24NCT01705795February 13, 201316 December 2017Anti-IL-5 Therapy in Bullous Pemphigoid (BP)Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid.Pemphigoid, BullousDrug: Mepolizumab (a-IL-5 antibody);Drug: PlaceboUniversity Hospital Inselspital, BerneNot recruiting18 YearsN/AAll32Phase 2Switzerland
25NCT01688882January 201319 October 2017Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid TreatmentA Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid TreatmentBullous PemphigoidDrug: QGE031;Drug: PlaceboNovartis PharmaceuticalsNot recruiting20 Years80 YearsAll20Phase 2United States;Austria;France;Germany;Japan;Taiwan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2012-003370-10-AT13/11/201210 July 2015Safety, efficacy and PK/PD of QGE031 vs. placebo in patients with active bullous phemphigoid despite oral steroid treatment.A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigoid with disease refractory to oral steroid treatmentRefractory Bullous Pemphigoid
MedDRA version: 15.0 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: QGE031
Pharmaceutical Form: Concentrate for solution for injection/infusion
Current Sponsor code: QGE031
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 120-
Pharmaceutical form of the placebo: Concentrate for solution for injection/infusion
Route of administration of the placebo: Subcutaneous use
Novartis Pharma AGNot RecruitingFemale: yes
Male: yes
42United States;Taiwan;Austria;Germany
27NCT01582880March 20124 November 2019Use of Cross-linked Donor Corneas as Carriers for the Boston KeratoprosthesisThe Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston KeratoprosthesisChemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune DiseasesDrug: RiboflavinJoseph B. Ciolino, MDNot recruiting18 YearsN/AAll1Phase 1/Phase 2United States
28NCT02202642January 201219 February 2015The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem CellsThe Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem CellsAlkaline Chemical Burn Of Cornea And Conjunctival Sac;Acid Chemical Burn Of Cornea And Conjunctival Sac;Benign Mucous Membrane Pemphigoid With Ocular InvolvementProcedure: collagenaseNational Taiwan University HospitalRecruiting18 Years70 YearsBoth10Phase 1Taiwan
29ChiCTR-TRC-120035382011-08-0118 April 2017Use of inravenous Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trialGuideline-oriented Research in the Management of Some Common and Severe Skin DiseasesBullous pemphigoidGlucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.;Institute of dermatology, Chinese Academy of Medical SciencesRecruiting180BothGlucocorticoids group:90;Glucocorticoid plus MTX group:90;Post-marketChina
30ChiCTR-TRC-120035922011-08-0118 April 2017Use of Tripterygium glycosides and Nicotinamide plus Minocycline for the Treatment of bullous pemphigoid: A multicenter,randomized and controlled clinincal trialGuideline-oriented Research in the Management of Some Common and Severe Skin DiseasesBullous pemphigoidTripterygium glycosides group:Take tripterygium glycosides orally at 20 mg, 3 times a day;Nicotinamide plus Minocycline group:Take nicotinamide at 500 mg, 3 times a day and minocycline 100 mg, twice a day.;Institute of dermatology, Chinese Academy of Medical SciencesNot Recruiting18BothTripterygium glycosides group:100;Nicotinamide plus Minocycline group:100;Post-marketChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31ChiCTR-TRC-120035932011-08-0118 April 2017Use of Oral Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trialGuideline-oriented Research in the Management of Some Common and Severe Skin Diseasesbullous pemphigoidGlucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses.;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.;Institute of dermatology; Chinese Academy of Medical SciencesNot Recruiting18BothGlucocorticoids group:90;Glucocorticoid plus MTX group:90;Post-marketChina
32NCT01408550August 201119 February 2015Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to CorticosteroidsNPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III)Bullous PemphigoidDrug: NPB-01;Drug: PlaceboNihon Pharmaceutical Co., LtdNot recruiting20 YearsN/ABoth56Phase 3Japan
33EUCTR2011-000756-42-DE15 July 2013Pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day.A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in patients with active bullous pemphigoidactive bullous pemphigoid
MedDRA version: 14.0 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: not applicable
Product Code: DF2156A
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: ladarixin
CAS Number: 865625-56-5
Current Sponsor code: DF2156A
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75-
Dompé s.p.a.Not RecruitingFemale: yes
Male: yes
12Phase 2Germany;Italy
34JPRN-UMIN0000044282010/11/012 April 2019Exploratory research on effectiveness and safety of Rituximab treatment for steroid intractable pemphygus, bullous pemphigoid and epidermolysis bullosa acquisita.pemphigus, bullous pemphigoid, epidermolysis bullosa acquisitaRituximabResearch group of rare intractable dermatologial disorderNot Recruiting20years-oldNot applicableMale and Female20Phase 2Japan
35ChiCTR-IOR-150071462009-10-0118 April 2017Combined treatment with low dose systemic steroids andtopical steroids in bullous pemphigoid andfactors of treatment-refractory bullous pemphigoidEfficacy of low dose systemic steroids combined with topical steroids in the treatment of bullous pemphigoid andrisk factors for treatment-refractory patients:A Randomized Controlled Trialbullous pemphigoidControl Group (C):apply 0.05% halometasone cream daily;Treatment Group (T):apply 0.05% halometasone cream daily+low-dose systemic steroids;Rui Jin Hospital, Shanghai Jiao Tong University School of MedicineNot RecruitingBothControl Group (C):40;Treatment Group (T):40;OtherChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36EUCTR2007-006658-24-GB05/03/200919 March 2012A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines StudyA randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines StudyBP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year.
MedDRA version: 14.0 Level: LLT Classification code 10006568 Term: Bullous pemphigoid NOS System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
MedDRA version: 14.0 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
Product Name: prednisolone
Pharmaceutical Form: Tablet
INN or Proposed INN: prednisolone
CAS Number: 50-24-8
Product Name: doxycycline
Pharmaceutical Form: Capsule
INN or Proposed INN: doxycycline
CAS Number: 50-24-8
Product Name: prednisolone
Pharmaceutical Form: Soluble tablet
INN or Proposed INN: prednisolone
CAS Number: 50-24-8
Product Name: prednisolone
Pharmaceutical Form: Coated tablet
INN or Proposed INN: prednisolone
CAS Number: 50-24-8
Product Name: doxycycline
Pharmaceutical Form: Dispersible tablet
INN or Proposed INN: doxycycline
CAS Number: 50-24-8
University of NottinghamAuthorisedFemale: yes
Male: yes
256Germany;United Kingdom
37EUCTR2008-005266-31-FR06/02/200919 March 2012COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab IIICOMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab IIIPemphogoide bulleuse
MedDRA version: 9.1 Level: LLT Classification code 10006567 Term: Bullous pemphigoid
Trade Name: mabthéra
Product Name: mathéra
Pharmaceutical Form: Solution for injection
Trade Name: Prednisone
Product Name: CORTANCYL 20 mg
Pharmaceutical Form: Tablet
CHU-Hôpitaux de RouenAuthorisedFemale: yes
Male: yes
France
38NCT00525616December 200819 February 2015Efficiency and Tolerance of Rituximab (mabthéra) in Bullous PemphigoidAssessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid.Bullous PemphigoidDrug: MabtheraUniversity Hospital, RouenNot recruiting18 Years80 YearsBoth18Phase 3France
39NCT00809822November 200819 February 2015Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase?).Bullous PemphigoidDrug: NPB-01;Drug: PlaceboNihon Pharmaceutical Co., LtdNot recruiting20 YearsN/ABoth20Phase 2Japan
40EUCTR2008-000480-41-IT27/05/200819 March 2012Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eye drop treatment on patients with ocular cicatricial pemphigoid. - NDMulticenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eye drop treatment on patients with ocular cicatricial pemphigoid. - NDOcular cicatricial pemphigoid (OCP)
MedDRA version: 9.1 Level: LLT Classification code 10010746 Term: Conjunctivitis chronic
Trade Name: RESTASIS
Pharmaceutical Form: Eye drops, suspension
INN or Proposed INN: Cyclosporine
Concentration unit: % percent
Concentration type: equal
Concentration number: .05-
Pharmaceutical form of the placebo: Eye drops, suspension
Route of administration of the placebo: Ocular use
UNIVERSITA' CAMPUS BIOMEDICOAuthorisedFemale: yes
Male: yes
Italy
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT02313870January 200819 February 2015Topical Steroids Alone or Associated With Methotrexate in Bullous PemphigoidComparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous PemphigoidBullous PemphigoidDrug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate aloneUniversity Hospital, MontpellierRecruiting18 YearsN/ABoth300Phase 3France
42EUCTR2007-003545-32-FR14/09/200719 March 2012Etude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes. - ARABULEtude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes. - ARABULPemphigoïde bulleuse
MedDRA version: 9.1 Level: LLT Classification code 10006567 Term: Bullous pemphigoid
Trade Name: ARAVA
Pharmaceutical Form: Tablet
Trade Name: DERMOVAL
Pharmaceutical Form: Cream
CHU de LimogesAuthorisedFemale: yes
Male: yes
France
43NCT00472030August 200719 October 2017Efficacy and Safety of Omalizumab in Bullous PemphigoidAn Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous PemphigoidBullous PemphigoidDrug: Omalizumab;Drug: prednisoneUniversity of IowaGenentech, Inc.Not recruiting18 YearsN/AAll2Phase 4United States
44NCT00584935January 200616 December 2017Clinical Trial Evaluating Rituximab in Ocular Cicatricial PemphigoidPhase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial PemphigoidOcular Cicatricial PemphigoidDrug: RituximabUniversity of Alabama at BirminghamGenentech, Inc.;BiogenNot recruiting19 YearsN/AAll3Phase 1/Phase 2United States
45EUCTR2005-001827-12-DE29/12/200519 March 2012Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept StudieMyfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept StudieBullous PemphigoidTrade Name: Myfortic 180 mg
Product Name: Myfortic 180 mg Filmtabletten
Pharmaceutical Form: Film-coated tablet
Georg-August-Universität Göttingen, Bereich HumanmedizinAuthorisedFemale: yes
Male: yes
10Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46EUCTR2005-002391-14-GB29/09/200518 April 2012Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoidPulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoidocular mucous membrane pemphigoidTrade Name: Solu-Medrone
Pharmaceutical Form: Powder for infusion*
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Moorfields Eye Hospital NHS Foundation TrustAuthorisedFemale: yes
Male: yes
20United Kingdom
47NCT00286325March 200519 October 2017Rituximab in the Treatment of Patients With Bullous PemphigoidRituximab in the Treatment of Patients With Bullous PemphigoidBullous PemphigoidDrug: RituximabDuke UniversityGenentech, Inc.Not recruiting18 YearsN/AAll8Phase 1/Phase 2United States
48NCT00213421August 200119 February 2015Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous PemphigusBullous PemphigoidDrug: DermovalUniversity Hospital, RouenNot recruiting18 YearsN/ABoth330Phase 4France
49NCT00431119October 199719 February 2015Azathioprine or Mycophenolate Mofetil for Bullous PemphigoidA Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous PemphigoidBullous PemphigoidDrug: Azathioprine or Mycophenolate mofetilUniversity Hospital MuensterHoffmann-La RocheNot recruiting18 Years90 YearsBoth70Phase 2Germany

先頭へ